Vir Biotechnology, Inc.

VIR

$746M

Small Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSAN FRANCISCO408 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

10 upcoming, 1 past

Phase 2Next

VIR-2218 Phase 2 Results Expected

March 2026~VIR-2218244

Primary completion for VIR-2218 trial (NCT04856085) in Hepatitis B, Chronic

Source

Phase 2

VIR-3434 Phase 2 Results Expected

March 2026~VIR-3434244

Primary completion for VIR-3434 trial (NCT04856085) in Hepatitis B, Chronic

Source

Phase 2

Tobevibart Phase 2 Results Expected

November 2026~Tobevibart100

Primary completion for Tobevibart trial (NCT07142811) in Viral Hepatitis

Source

Phase 2

Elebsiran Phase 2 Results Expected

November 2026~Elebsiran100

Primary completion for Elebsiran trial (NCT07142811) in Viral Hepatitis

Source

Phase 2

Bulevirtide Phase 2 Results Expected

November 2026~Bulevirtide100

Primary completion for Bulevirtide trial (NCT07142811) in Viral Hepatitis

Source

⭐Phase 3

Bulevirtide Phase 3 Results Expected

December 2026~Bulevirtide150

Primary completion for Bulevirtide trial (NCT07128550) in Viral Hepatitis

Source

⭐Phase 3

Tobevibart Phase 3 Results Expected

December 2026~Tobevibart150

Primary completion for Tobevibart trial (NCT07128550) in Viral Hepatitis

Source

⭐Phase 3

Elebsiran Phase 3 Results Expected

December 2026~Elebsiran150

Primary completion for Elebsiran trial (NCT07128550) in Viral Hepatitis

Source

⭐Phase 3

Tobevibart Phase 3 Results Expected

Dec 31, 2026Tobevibart124

Primary completion for Tobevibart trial (NCT06903338) in Viral Hepatitis

Source

⭐Phase 3

Elebsiran Phase 3 Results Expected

Dec 31, 2026Elebsiran124

Primary completion for Elebsiran trial (NCT06903338) in Viral Hepatitis

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Tobevibart

Phase 3

Viral Hepatitis

Elebsiran

Phase 3

Viral Hepatitis

VIR-7831 (sotrovimab)

Phase 3

Covid19

Bulevirtide

Phase 3

Viral Hepatitis

NRTI

Phase 2

Hepatitis D, Chronic

VIR-2218

Phase 2

Hepatitis B, Chronic

pegylated interferon-alfa 2a

Phase 2

Chronic Hepatitis B

VIR-5818

Phase 2

Locally Advanced or Metastatic HER2-Expressing Cancers

Sotrovimab (Gen1)

Phase 2

Covid19

VIR-3434

Phase 2

Hepatitis B, Chronic

Drug Name	Phase	Indication	Designations
Tobevibart	Phase 3	Viral Hepatitis	-
Elebsiran	Phase 3	Viral Hepatitis	-
VIR-7831 (sotrovimab)	Phase 3	Covid19	-
Bulevirtide	Phase 3	Viral Hepatitis	-
NRTI	Phase 2	Hepatitis D, Chronic	-
VIR-2218	Phase 2	Hepatitis B, Chronic	-
pegylated interferon-alfa 2a	Phase 2	Chronic Hepatitis B	-
VIR-5818	Phase 2	Locally Advanced or Metastatic HER2-Expressing Cancers	-
Sotrovimab (Gen1)	Phase 2	Covid19	-
VIR-3434	Phase 2	Hepatitis B, Chronic	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

VIR News